Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

CLINICAL QUESTION: What is the optimal platelet count threshold for prophylactic platelet transfusions to minimize bleeding, platelet use, and adverse clinical outcomes in thrombocytopenic patients with hematological malignant neoplasms? BOTTOM LINE: Maintaining a higher platelet count threshold (≤20 × 109/L or ≤30 × 109/L) was not associated with less bleeding than the current standard (≤10 × 109/L), but required more platelet transfusions (low-quality evidence).

Original publication

DOI

10.1001/jamaoncol.2016.2466

Type

Journal article

Journal

JAMA Oncol

Publication Date

01/08/2016

Volume

2

Pages

1091 - 1092

Keywords

Antineoplastic Agents, Hematologic Diseases, Hematopoietic Stem Cell Transplantation, Hemorrhage, Humans, Leukemia, Platelet Count, Platelet Transfusion, Thrombocytopenia